Intranasally administered neuropeptide S (NPS) exerts anxiolytic effects following internalization into NPS receptor-expressing neurons

Neuropsychopharmacology

Volumn 37, Issue 6, 2012, Pages 1323-1337

  Ionescu, Irina A ^a   Dine, Julien ^a   Yen, Yi Chun ^a   Buell, Dominik R ^a   Herrmann, Leonie ^a   Holsboer, Florian ^a   Eder, Matthias ^a   Landgraf, Rainer ^a   Schmidt, Ulrike ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

anxiety; GPCR internalization; hippocampal plasticity; intranasal drug delivery; neuropeptide S (NPS); post traumatic stress disorder (PTSD)

Indexed keywords

GLUTAMIC ACID; LIGAND; NEUROPEPTIDE RECEPTOR; NEUROPEPTIDE S;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; HIPPOCAMPAL CA1 REGION; INTERNALIZATION; MALE; MOUSE; NERVE CELL; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; SYNAPTIC TRANSMISSION; TRANQUILIZING ACTIVITY;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; CA1 REGION, HIPPOCAMPAL; CARBOCYANINES; CELL LINE, TRANSFORMED; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; EVOKED POTENTIALS; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; GREEN FLUORESCENT PROTEINS; HUMANS; INTRAVITREAL INJECTIONS; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; NEUROFILAMENT PROTEINS; NEURONS; NEUROPEPTIDES; OXAZOLIDINONES; PROTEIN TRANSPORT; PYRAZINES; RECEPTORS, AMPA; RECEPTORS, NEUROPEPTIDE; RHODAMINES; RNA, MESSENGER; SYNAPSINS; TRANSFECTION;

EID: 84859786232     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.317     Document Type: Article

References (64)

1. Bailey KR, Pavlova MN, Rohde AD, Hohmann JG, Crawley JN (2007). Galanin receptor subtype 2 (GalR2) null mutant mice display an anxiogenic-like phenotype specific to the elevated plus-maze. Pharmacol Biochem Behav 86: 8-20.
2. Blanco E, Bilbao A, Luque-Rojas MJ, Palomino A, Bermúdez-Silva FJ, Suárez J et al (2011). Attenuation of cocaine-induced conditioned locomotion is associated with altered expression of hippocampal glutamate receptors in mice lacking LPA1 receptors. Psychopharmacology; e-pub ahead of print 2 September 2011.
3. Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL (2002). Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 5: 514-516. (Pubitemid 34568991)
4. Bunck M, Czibere L, Horvath C, Graf C, Frank E, Kessler MS et al (2009). A hypomorphic vasopressin allele prevents anxietyrelated behavior. PLoS ONE 4: e5129.
5. Bunnett NW, Dazin PF, Payan DG, Grady EF (1995). Characterization of receptors using cyanine 3-labeled neuropeptides. Peptides 16: 733-740.
6. Camarda V, Rizzi A, Ruzza C, Zucchini S, Marzola G, Marzola E et al (2009). In vitro and in vivo pharmacological characterization of the neuropeptide s receptor antagonist [D-Cys(tBu)5]-neuropeptide S. J Pharmacol Exp Ther 328: 549-555.
7. Cao J, de Lecea L, Ikemoto S (2011). Intraventricular administration of neuropeptide S has reward-like effects. Eur J Pharmacol 658: 16-21.
8. Cesca F, Baldelli P, Valtorta F, Benfenati F (2010). The synapsins: key actors of synapse function and plasticity. Prog Neurobiol 91: 313-348.
9. Cloos J-M, Ferreira V (2009). Current use of benzodiazepines in anxiety disorders. Curr Opin Psychiatry 22: 90-95.
10. de Kloet ER, Joëls M, Holsboer F (2005). Stress and the brain: from adaptation to disease. Nat Rev Neurosci 6: 463-475. (Pubitemid 40769171)
11. Dhuria SV, Hanson LR, Frey WH (2009a). Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system. J Pharm Sci 98: 2501-2515.
12. Dhuria SV, Hanson LR, Frey WH (2009b). Novel vasoconstrictor formulation to enhance intranasal targeting of neuropeptide therapeutics to the central nervous system. J Pharmacol Exp Ther 328: 312-320.
13. Dhuria SV, Hanson LR, Frey WH (2010). Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 99: 1654-1673.
14. Domschke K, Reif A, Weber H, Richter J, Hohoff C, Ohrmann P et al (2010). Neuropeptide S receptor geneFconverging evidence for a role in panic disorder. Mol Psychiatry 16: 938-948.
15. Dufes C, Olivier J-C, Gaillard F, Gaillard A, Couet W, Muller J-M (2003). Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats. Int J Pharm 255: 87-97. (Pubitemid 36369593)
16. Fanselow MS, Dong H-W (2010). Are the dorsal and ventral hippocampus functionally distinct structures? Neuron 65: 7-19.
17. Fendt M, Imobersteg S, Bürki H, McAllister KH, Sailer AW (2010). Intra-amygdala injections of neuropeptide S block fear-potentiated startle. Neurosci Lett 474: 154-157.
18. Franklin KBJ, Paxinos G (2007). The Mouse Brain in Stereotaxic Coordinates with CDROM, 3rd edn. Academic Press, New York, NY, USA.
19. Furukawa TA, Watanabe N, Churchill R (2006). Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: systematic review. Br J Psychiatry 188: 305-312.
20. Grady E, Garland A, Gamp P, Lovett M, Payan D, Bunnett N (1995). Delineation of the endocytic pathway of substance P and its seven-transmembrane domain NK1 receptor. Mol Biol Cell 6: 509-524.
21. Guastella AJ, Einfeld SL, Gray KM, Rinehart NJ, Tonge BJ, Lambert TJ et al (2010). Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry 67: 692-694.
22. Gupte J, Cutler G, Chen J-L, Tian H (2004). Elucidation of signaling properties of vasopressin receptor-related receptor 1 by using the chimeric receptor approach. Proc Natl Acad Sci USA 101: 1508-1513. (Pubitemid 38234185)
23. Hambsch B, Chen B-G, Brenndörfer J, Meyer M, Avrabos C, Maccarrone G et al (2010). Methylglyoxal-mediated anxiolysis involves increased protein modification and elevated expression of glyoxalase 1 in the brain. J Neurochem 113: 1240-1251.
24. Han R-W, Yin X-Q, Chang M, Peng Y-L, Li W, Wang R (2009). Neuropeptide S facilitates spatial memory and mitigates spatial memory impairment induced by N-methyl-D-aspartate receptor antagonist in mice. Neurosci Lett 455: 74-77.
25. Hökfelt T, Bartfai T, Bloom F (2003). Neuropeptides: opportunities for drug discovery. Lancet Neurol 2: 463-472. (Pubitemid 36876103)
26. Huang YH, Bergles DE (2004). Glutamate transporters bring competition to the synapse. Curr Opin Neurobiol 14: 346-352. (Pubitemid 38759865)
27. Hubbard CS, Dolence EK, Shires JA, Rose JD (2009). Identification of brain target neurons using a fluorescent conjugate of corticotropin-releasing factor. J Chem Neuroanat 37: 245-253.
28. Isaac JTR, Ashby M, McBain CJ (2007). The role of the GluR2 subunit in AMPA receptor function and synaptic plasticity. Neuron 54: 859-871. (Pubitemid 46907505)
29. Jansson B, Björk E (2002). Visualization of in vivo olfactory uptake and transfer using fluorescein dextran. J Drug Target 10: 379-386.
30. Jüngling K, Seidenbecher T, Sosulina L, Lesting J, Sangha S, Clark SD et al (2008). Neuropeptide S-mediated control of fear expression and extinction: role of intercalated GABAergic neurons in the amygdala. Neuron 59: 298-310. (Pubitemid 352033690)
31. Krömer SA, Kessler MS, Milfay D, Birg IN, Bunck M, Czibere L et al (2005). Identification of glyoxalase-I as a protein marker in a mouse model of extremes in trait anxiety. J Neurosci 25: 4375-4384. (Pubitemid 40628782)
32. Landgraf R, Kessler MS, Bunck M, Murgatroyd C, Spengler D, Zimbelmann M et al (2007). Candidate genes of anxiety-related behavior in HAB/LAB rats and mice: focus on vasopressin and glyoxalase-I. Neurosci Biobehav Rev 31: 89-102. (Pubitemid 44880077)
33. Leonard SK, Dwyer JM, Sukoff Rizzo SJ, Platt B, Logue SF, Neal SJ et al (2008). Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders. Psychopharmacology (Berl) 197: 601-611.
34. Leonard SK, Ring RH (2011). Immunohistochemical localization of the neuropeptide S receptor in the rat central nervous system. Neuroscience 172: 153-163.
35. Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(Delta Delta C(T)) method. Methods 25: 402-408. (Pubitemid 34164012)
36. Meis S, Bergado-Acosta JR, Yanagawa Y, Obata K, Stork O, Munsch T (2008). Identification of a neuropeptide s responsive circuitry shaping amygdala activity via the endopiriform nucleus. PLoS ONE 3: e2695.
37. Ohkubo K, Okuda M, Kaliner MA (1994). Immunological localization of neuropeptide-degrading enzymes in the nasal mucosa. Rhinology 32: 130-133. (Pubitemid 24344340)
38. Okamura N, Garau C, Duangdao DM, Clark SD, Jüngling K, Pape H-C et al (2010). Neuropeptide S enhances memory during the consolidation phase and interacts with noradrenergic systems in the brain. Neuropsychopharmacology 36: 744-752.
39. Okamura N, Habay SA, Zeng J, Chamberlin AR, Reinscheid RK (2008). Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the neuropeptide S receptor. J Pharmacol Exp Ther 325: 893-901. (Pubitemid 351724341)
40. Ozsoy Y, Gungor S, Cevher E (2009). Nasal delivery of high molecular weight drugs. Molecules 14: 3754-3779.
41. Perisic T, Zimmermann N, Kirmeier T, Asmus M, Tuorto F, Uhr M et al (2010). Valproate and amitriptyline exert common and divergent influences on global and gene promoter-specific chromatin modifications in rat primary astrocytes. Neuropsychopharmacology 35: 792-805.
42. Raiteri L, Luccini E, Romei C, Salvadori S, Calò G (2009). Neuropeptide S selectively inhibits the release of 5-HT and noradrenaline from mouse frontal cortex nerve endings. Br J Pharmacol 157: 474-481.
43. Ravindran LN, Stein MB (2009). Pharmacotherapy of PTSD: premises, principles, and priorities. Brain Res 1293: 24-39.
44. Reinscheid RK, Xu Y-L, Okamura N, Zeng J, Chung S, Pai R et al (2005). Pharmacological characterization of human and murine neuropeptide s receptor variants. J Pharmacol Exp Ther 315: 1338-1345. (Pubitemid 41635423)
45. Reyes BAS, Fox K, Valentino RJ, Van Bockstaele EJ (2006). Agonist-induced internalization of corticotropin-releasing factor receptors in noradrenergic neurons of the rat locus coeruleus. Eur J Neurosci 23: 2991-2998. (Pubitemid 43882878)
46. Rodrigues H, Figueira I, Gonçalves R, Mendlowicz M, Macedo T, Ventura P (2011). CBT for pharmacotherapy non-remittersF a systematic review of a next-step strategy. J Affect Disord 129: 219-228.
47. Rossi S, De Capua A, Tavanti M, Calossi S, Polizzotto NR, Mantovani A et al (2009). Dysfunctions of cortical excitability in drug-na?̈ve posttraumatic stress disorder patients. Biol Psychiatry 66: 54-61.
48. Schmidt MV, Schülke J-P, Liebl C, Stiess M, Avrabos C, Bock J et al (2011). Tumor suppressor downregulated in renal cell carcinoma 1 (DRR1) is a stress-induced actin bundling factor that modulates synaptic efficacy and cognition. Proc Natl Acad Sci USA 108: 17213-17218.
49. Shi C-G, Wang L-M, Wu Y, Wang P, Gan Z-J, Lin K et al (2010). Intranasal administration of nerve growth factor produces antidepressant-like effects in animals. Neurochem Res 35: 1302-1314.
50. Si W, Aluisio L, Okamura N, Clark SD, Fraser I, Sutton SW et al (2010). Neuropeptide S stimulates dopaminergic neurotransmission in the medial prefrontal cortex. J Neurochem 115: 475-482.
51. Smith KL, Patterson M, Dhillo WS, Patel SR, Semjonous NM, Gardiner JV et al (2006). Neuropeptide S stimulates the hypothalamo-pituitary-adrenal axis and inhibits food intake. Endocrinology 147: 3510-3518. (Pubitemid 43901142)
52. Tan KR, Brown M, Labouèbe G, Yvon C, Creton C, Fritschy J-M et al (2010). Neural bases for addictive properties of benzodiazepines. Nature 463: 769-774.
53. Thorne RG, Emory CR, Ala TA, Frey WH (1995). Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res 692: 278-282.
54. Thorne RG, Frey WH (2001). Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet 40: 907-946. (Pubitemid 34066688)
55. Thorne RG, Hanson LR, Ross TM, Tung D, Frey WH (2008). Delivery of interferon-beta to the monkey nervous system following intranasal administration. Neuroscience 152: 785-797.
56. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH (2004). Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127: 481-496. (Pubitemid 38950662)
57. Trapella C, Pela M, Del Zoppo L, Calo G, Camarda V, Ruzza C et al (2011). Synthesis and separation of the enantiomers of the neuropeptide S receptor antagonist (9R/S)-3-oxo-1,1-diphenyltetrahydro-oxazolo[3,4-a]pyrazine-7- carboxylic acid 4-fluorobenzylamide (SHA 68). J Med Chem 54: 2738-2744.
58. Van den Berg MP, Romeijn SG, Verhoef JC, Merkus FWHM (2002). Serial cerebrospinal fluid sampling in a rat model to study drug uptake from the nasal cavity. J Neurosci Methods 116: 99-107. (Pubitemid 34465788)
59. Van Gaalen MM, Steckler T (2000). Behavioural analysis of four mouse strains in an anxiety test battery. Behav Brain Res 115: 95-106.
60. Vendelin J, Bruce S, Holopainen P, Pulkkinen V, Rytilä P, Pirskanen A et al (2006). Downstream target genes of the neuropeptide S-NPSR1 pathway. Hum Mol Genet 15: 2923-2935. (Pubitemid 44446811)
61. Xu Y-L, Gall CM, Jackson VR, Civelli O, Reinscheid RK (2007). Distribution of neuropeptide S receptor mRNA and neurochemical characteristics of neuropeptide S-expressing neurons in the rat brain. J Comp Neurol 500: 84-102. (Pubitemid 44904303)
62. Xu Y-L, Reinscheid RK, Huitron-Resendiz S, Clark SD, Wang Z, Lin SH et al (2004). Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron 43: 487-497. (Pubitemid 39094676)
63. Zhu H, Mingler MK, McBride ML, Murphy AJ, Valenzuela DM, Yancopoulos GD et al (2010). Abnormal response to stress and impaired NPS-induced hyperlocomotion, anxiolytic effect and corticosterone increase in mice lacking NPSR1. Psychoneuroendocrinology 35: 1119-1132.
64. Zushida K, Sakurai M, Wada K, Sekiguchi M (2007). Facilitation of extinction learning for contextual fear memory by PEPA: a potentiator of AMPA receptors. J Neurosci 27: 158-166. (Pubitemid 46089970)